News about Global Pharma

Innocan Pharma Submits Application for FDA Pre-IND Meeting for CBD Therapy to Combat Chronic Pain

The global pain therapeutics market, expected to surpass USD 100 billion by 2032, highlights the pressing need for effective alternatives to opioid-based treatments.

Global Pharma | 23/04/2024 | By Abha |  539

Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus

Eli Lilly has signed a definitive agreement with Nexus Pharmaceuticals wherein Lilly will be acquiring a manufacturing facility from Nexus.

Global Pharma | 23/04/2024 | By Aishwarya |  630

Panasonic and Shinobi Therapeutics to Develop iPS Cell Therapy Manufacturing Tech

Shinobi Therapeutics has joined hands with Panasonic Holdings Corp. and Kyoto University's Center for iPS Cell Research and Application (CiRA).

Global Pharma | 23/04/2024 | By Aishwarya |  218

PharmaLogic Opens New Radiopharmaceutical Production Facility in Cincinnati

PharmaLogic Holdings Corp. has opened its new radiopharmaceutical production and research facility in Cincinnati, Ohio.

Global Pharma | 23/04/2024 | By Aishwarya |  930

Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC

Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.

Global Pharma | 23/04/2024 | By Aishwarya |  403

Ipsen and Skyhawk Therapeutics to Work on RNA Targeting Research in Rare Neurological Diseases

Ipsen has signed an exclusive worldwide collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.

Global Pharma | 22/04/2024 | By Aishwarya |  512

Essential Pharma Acquires Reminyl Oral Capsules

Essential Pharma has completed the acquisition of Reminyl oral capsules from Janssen Pharmaceutica NV.

Global Pharma | 22/04/2024 | By Aishwarya |  343

SIIPL Signs Licensing Agreement with University of Oxford for Meningitis-B Vaccine

Serum Institute of India Pvt. Ltd. (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation in a significant stride towards addressing the challenge of Men-B disease.

Global Pharma | 22/04/2024 | By Aishwarya |  710

Genentech Receives Approval from FDA for Alecensa

Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

Global Pharma | 22/04/2024 | By Aishwarya |  753

CordenPharma, GENEPEP Celebrate Strong Alliance for Developing Peptide Drug Substance

CordenPharma and GENEPEP have recently celebrated one year of their fruitful collaboration.

Global Pharma | 20/04/2024 | By Aishwarya |  546